Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Read the full article here: https://www.emergers.se/prolight_e/ For further information, please contact:Ulf Bladin, CEOE-mail: ub@prolightdx.comPhone: +46 73 582 39 87 Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.We want to offer the foremost […]
Prolight Diagnostics publishes half-year report, 2024
Financial overviewSecond quarter, April 1 – June 30, Q2 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 18 (101) thousand. The profit after tax amounted to SEK -11,224 (-8,033) thousand. Earnings per share before and after dilution: -0.02 […]
Prolight Diagnostics presents the Psyros system at ADLM, one of the world’s largest and most important diagnostics congresses
Prolight Diagnostics (“Prolight”), developer of the Psyros™ digital point-of-care (POC) system for high-sensitivity troponin, announces that the platform will be showcased at DxPxduring the international congress ADLM in Chicago July 28-August 1, 2024. “We are very proud to present the latest commercial instrument prototype and the cartridge that will be used for high-sensitivity troponin assays. […]
Warrants of series TO6 were exercised to approximately 44.8 percent and Prolight Diagnostics receives approximately SEK 9.8 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight has obtained subscription commitments for exercising warrants of series TO6 from, among others, members of the Board and management of approximately SEK 1.0 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Last day of trading with warrants of series TO6 in Prolight Diagnostics is today, May 28, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Annual general meeting of Prolight Diagnostics AB (publ) on 27 May 2024
The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 27 May 2024 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight on track for clinical performance studies
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, announces today that their latest data for troponin in whole blood confirm that the company is now ready to initiate trials with patient samples. The latest data were generated in whole blood samples on the final commercial cartridge design, which now includes internal cartridge quality controls […]
Prolight initiates trial at London hospital Trust supported by an NIHR i4i PDA grant
Prolight Diagnostics today announces the company will initiate a trial at Guy’s and St Thomas’NHS Foundation Trust and King’s College London to pre-validate assay and prototype performance of the Psyros™ POC system. The trial is supported by the recently awarded NIHR i4i PDA grant. Initial data with patient samples will be generated in Q3 2024 […]
The exercise period for warrants of series TO6 in Prolight Diagnostics begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
